299 related articles for article (PubMed ID: 25132756)
1. Pancreatic cancer-improved care achievable.
Buanes TA
World J Gastroenterol; 2014 Aug; 20(30):10405-18. PubMed ID: 25132756
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors related with survival in patients with pancreatic adenocarcinoma.
Bilici A
World J Gastroenterol; 2014 Aug; 20(31):10802-12. PubMed ID: 25152583
[TBL] [Abstract][Full Text] [Related]
3. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
4. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.
Buanes TA
World J Gastroenterol; 2016 Dec; 22(48):10502-10511. PubMed ID: 28082802
[TBL] [Abstract][Full Text] [Related]
5. Role of surgery in pancreatic cancer.
Buanes TA
World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
[TBL] [Abstract][Full Text] [Related]
6. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
8. Resection and radiochemotherapy of pancreatic cancer--the future?
Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
10. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
11. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review.
Attard JA; Farrugia A; Pathanki A; Roberts KJ; Dasari B; Isaac J; Ma YT; Chatzizacharias NA
Pancreas; 2020; 49(10):1264-1275. PubMed ID: 33122513
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
14. Approach to patients with pancreatic cancer without detectable metastases.
Heestand GM; Murphy JD; Lowy AM
J Clin Oncol; 2015 Jun; 33(16):1770-8. PubMed ID: 25918279
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
16. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
17. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
Polish A; Joseph NE; Marsh RW
Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?
Reni M
World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
Motoi F; Unno M
Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
